Alzamend Neuro reports Phase II AL001 trial meets bioequivalence; whole-brain lithium exposure rises ~7.8% vs. lithium carbonate

Reuters03-26

<a href="https://laohu8.com/S/ALZN">Alzamend Neuro</a> reports Phase II AL001 trial meets bioequivalence; whole-brain lithium exposure rises ~7.8% vs. lithium carbonate

Alzamend reported topline results from a Phase II “Lithium in Brain” trial in healthy subjects evaluating AL001 versus standard lithium carbonate.
Systemic exposure met bioequivalence criteria, with AL001 delivering 101% of total lithium blood exposure and 97% of peak lithium levels versus lithium carbonate.
Brain imaging analyses showed numerically higher lithium concentrations for AL001 across 26 measured brain regions, including an approximately 7.8% higher maximum whole-brain lithium exposure versus lithium carbonate.
Time to peak brain lithium concentration was 6.7 hours for AL001 compared with 8.4 hours for lithium carbonate.
A second Phase II “Lithium in Brain” trial in bipolar disorder patients is underway, with topline data expected in Q3 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alzamend Neuro Inc. published the original content used to generate this news brief on March 26, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622524168?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622524168","market":"fut","top_or_hot":-1,"title":"Alzamend Neuro reports Phase II AL001 trial meets bioequivalence; whole-brain lithium exposure rises ~7.8% vs. lithium carbonate","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ALZN\">Alzamend Neuro</a> reports Phase II AL001 trial meets bioequivalence; whole-brain lithium exposure rises ~7.8% vs. lithium carbonate\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Alzamend reported topline results from a Phase II “Lithium in Brain” trial in healthy subjects evaluating AL001 versus standard lithium carbonate.\n        </li>\n<li>\n          Systemic exposure met bioequivalence criteria, with AL001 delivering 101% of total lithium blood exposure and 97% of peak lithium levels versus lithium carbonate.\n        </li>\n<li>\n          Brain imaging analyses showed numerically higher lithium concentrations for AL001 across 26 measured brain regions, including an approximately 7.8% higher maximum whole-brain lithium exposure versus lithium carbonate.\n        </li>\n<li>\n          Time to peak brain lithium concentration was 6.7 hours for AL001 compared with 8.4 hours for lithium carbonate.\n        </li>\n<li>\n          A second Phase II “Lithium in Brain” trial in bipolar disorder patients is underway, with topline data expected in Q3 2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alzamend Neuro Inc. published the original content used to generate this news brief on March 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alzamend Neuro reports Phase II AL001 trial meets bioequivalence; whole-brain lithium exposure rises ~7.8% vs. lithium carbonate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlzamend Neuro reports Phase II AL001 trial meets bioequivalence; whole-brain lithium exposure rises ~7.8% vs. lithium carbonate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-26 20:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ALZN\">Alzamend Neuro</a> reports Phase II AL001 trial meets bioequivalence; whole-brain lithium exposure rises ~7.8% vs. lithium carbonate\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Alzamend reported topline results from a Phase II “Lithium in Brain” trial in healthy subjects evaluating AL001 versus standard lithium carbonate.\n        </li>\n<li>\n          Systemic exposure met bioequivalence criteria, with AL001 delivering 101% of total lithium blood exposure and 97% of peak lithium levels versus lithium carbonate.\n        </li>\n<li>\n          Brain imaging analyses showed numerically higher lithium concentrations for AL001 across 26 measured brain regions, including an approximately 7.8% higher maximum whole-brain lithium exposure versus lithium carbonate.\n        </li>\n<li>\n          Time to peak brain lithium concentration was 6.7 hours for AL001 compared with 8.4 hours for lithium carbonate.\n        </li>\n<li>\n          A second Phase II “Lithium in Brain” trial in bipolar disorder patients is underway, with topline data expected in Q3 2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alzamend Neuro Inc. published the original content used to generate this news brief on March 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALZN","symbol_name":"Alzamend Neuro, Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL4n8tg1:1","article_id":"2622524168","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622524168","pubTimestamp":1774526495,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Alzamend Neuro reports Phase II AL001 trial meets bioequivalence; whole-brain lithium exposure rises ~7.8% vs. lithium carbonate. Alzamend reported topline results from a Phase II “Lithium in Brain” trial in healthy subjects evaluating AL001 versus standard lithium carbonate.Systemic exposure met bioequivalence criteria, with AL001 delivering 101% of total lithium blood exposure and 97% of peak lithium levels versus lithium carbonate.Brain imaging analyses showed numerically higher lithium concentrations for AL001 across 26 measured brain regions, including an approximately 7.8% higher maximum whole-brain lithium exposure versus lithium carbonate.Time to peak brain lithium concentration was 6.7 hours for AL001 compared with 8.4 hours for lithium carbonate.A second Phase II “Lithium in Brain” trial in bipolar disorder patients is underway, with topline data expected in Q3 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALZN":"Alzamend Neuro, Inc","BK4139":"生物科技","BK4539":"次新股"},"translate_title":"Alzamend Neuro报告II期AL001试验符合生物等效性；与碳酸锂相比，全脑锂暴露量增加了约7.8%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALZN":0.9},"content_text":"Alzamend Neuro reports Phase II AL001 trial meets bioequivalence; whole-brain lithium exposure rises ~7.8% vs. lithium carbonate\n    \n\n\n          Alzamend reported topline results from a Phase II “Lithium in Brain” trial in healthy subjects evaluating AL001 versus standard lithium carbonate.\n        \n\n          Systemic exposure met bioequivalence criteria, with AL001 delivering 101% of total lithium blood exposure and 97% of peak lithium levels versus lithium carbonate.\n        \n\n          Brain imaging analyses showed numerically higher lithium concentrations for AL001 across 26 measured brain regions, including an approximately 7.8% higher maximum whole-brain lithium exposure versus lithium carbonate.\n        \n\n          Time to peak brain lithium concentration was 6.7 hours for AL001 compared with 8.4 hours for lithium carbonate.\n        \n\n          A second Phase II “Lithium in Brain” trial in bipolar disorder patients is underway, with topline data expected in Q3 2026.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alzamend Neuro Inc. published the original content used to generate this news brief on March 26, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622524168","isCrawlerRequest":true}